List view / Grid view
8 June 2016 | By Victoria White, Digital Content Producer
The OPAL Beyond study met its primary efficacy endpoints demonstrating a statistically significant improvement with tofacitinib 5 mg BID and 10 mg BID...
24 March 2016 | By Victoria White
Xeljanz is the only oral Janus kinase (JAK) inhibitor approved in more than 45 countries around the world for the treatment of moderate to severe RA...
3 July 2015 | By Victoria White
The FDA has accepted for review Pfizer’s new drug application (NDA) for Xeljanz (tofacitinib citrate) 11 mg once daily modified release tablets...
11 June 2014 | By Pfizer
Additional data further characterizes the safety profile of XELJANZ...
25 September 2013 | By Pfizer
Long-term safety and efficacy data of XELJANZ up to five years will be presented at the American College Of Rheumatology 2013 annual meeting...
16 July 2013 | By Pfizer Inc.
Pfizer provides update on XELJANZ® (tofacitinib citrate) for the treatment of rheumatoid arthritis...
25 April 2013 | By Pfizer
Pfizer intends to appeal and seek re-examination...
25 March 2013 | By Pfizer
“RA is a serious and disabling disease and there is a need for new treatment options..."
6 November 2012 | By Pfizer
The U.S. FDA has approved XELJANZ®...
